A dynamic look at the current research done in Molecular imaging with different applications of ImmunoPET in medicine.

1. Molecular Immuno-Imaging
Charles Hall

2. Pharmaco-Definitions
Pharmacokinetics Pharmacodynamics
Absorption/Binding Affinity Effects of drugs
Distribution Mechanism of drug action
Rate of Drug Action/Duration Dosage/Concentration effects
Metabolism/Biotransformation
Elimination/Clearance
Quote: “Pharmacokinetics may be simply defined as
what the body does to the drug, as opposed to
pharmacodynamics which may be defined as what the
drug does to the body” - Leslie Z. Benet

3. Background
J591
89Zr
DFO
18F-FEAU
Prostate Cancer and PSMA
Adoptive Transfer of CTL’s

4. Bander mAb
J591 was licensed to BZL Biologics by Bander and, in association with
Millenium pharmaceuticals, has agreed to develop this and other
prostate cancer targeting compounds. Recently this paper showed that
J591 fixed to a surface could bind LNCaP cells showing efficacy in
immunocapture and clearance of metastases from the blood.

5. Gene Therapy

6. Math concepts
DFT
Standardized Uptake Value
SUV = measured activity concentration (Bq/g) x body weight (g)
injected activity (Bq)
Biodistribution
%ID/g uptake
Stability
Demetalation over time in saline or BSA

7. Density Functional Theory
Alternative to Crystallization
Computer Generated with Gaussian03, ab initio quantum chemistry program
Probe of structure, bonding and chemical/thermodyamic stability

8. Comparison of Technologies
PET Location Radioprobes Cell specific
CT Density X-ray Bones
MRI Contrast Magnets Soft Tissue
PET/CT and PET/MR Biochemistry meets Anatomy

9. Reporter Gene
Pharmacokinetic in nature, Pharmacodynamic in
application

10. Retroviral Transduction

11. Figure 1

12. Figure 1
continued

13. Figure 2

14. Figure 2 cont’d

15. Figure 3

18. Radiotracer of expression
Pharmacokinetic

19. 89Zr-DFO Formation

20. Chemistry
Chelation
less than two hours, 3.9 chelates per mAb
Immunoreactivity following radiolabeling
Immunoreactive fraction high after 7 days

21. Figure 2

22. Figure 3

25. Figure 4

26. Figure 5

28. Conclusions
Both papers showed the efficacy of radiotracers in
monitoring cells of interest, for the sake of treatment
or for monitoring disease progression
Both systems also could be used more specifically in a
pharmacodynamic application of the information
obtained from their initial pharmacokinetic work
presented today

29. The End